
"I am glad that taking part in a trial might help others on their own cancer journey.”
This trial was comparing doxorubicin with 2 different ways of having ifosfamide for advanced soft tissue sarcoma.
Doctors often use chemotherapy to treat soft tissue sarcoma. Doxorubicin is the drug they most commonly use.
In this trial, the researchers compared doxorubicin with a drug called ifosfamide. They looked at 2 different ways of having ifosfamide.
The aims of the trial were to
The trial team found that ifosfamide was no better at treating soft tissue sarcoma than doxorubicin.
The trial recruited 326 people
Side effects such as a drop in the number of blood cells, infections and changes to the were more common with ifosfamide.
The trial team followed the progress of the people who took part for an average of over 3 and a half years. They found that the number of people whose cancer had responded to the treatment, and the number of people whose cancer had not come back, was about the same in all 3 groups.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists () and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Paul Lorigan
European Organisation for Research and Treatment of Cancer (EORTC)
Freephone 0808 800 4040
"I am glad that taking part in a trial might help others on their own cancer journey.”